You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial

Authors

  • Alex De Caluwe Radiation Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Emanuela Romano Medical Oncology, Center for Cancer Immunotherapy, Institut Curie, Paris, France PubMed articlesGoogle scholar articles
  • Philip Poortmans Radiation Oncology, Iridium Network and University of Antwerp, Antwerpen, Belgium PubMed articlesGoogle scholar articles
  • Andrea Gombos Medical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Elisa Agostinetto Clinical Trials Support Unit (CTSU), Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Guilherme Nader Marta Clinical Trials Support Unit (CTSU), Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Zoe Denis Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Stylianos Drisis Radiology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Christophe Vandekerkhove Medical Physics, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Antoine Desmet Radiation Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Catherine Philippson Radiation Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Ligia Craciun Pathology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Isabelle Veys Surgery, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Denis Larsimont Pathology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Marianne Paesmans Clinical Trials Support Unit (CTSU), Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Dirk Van Gestel Radiation Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Roberto Salgado Pathology, GasthuisZusters Antwerpen, Antwerpen, Belgium PubMed articlesGoogle scholar articles
  • Christos Sotiriou Medical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Martine Piccart-Gebhart Medical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Michail Ignatiadis Medical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles
  • Laurence Buisseret Medical Oncology, Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Institut Jules Bordet, Bruxelles, Belgium PubMed articlesGoogle scholar articles

Citation

De Caluwe A, Romano E, Poortmans P, et al
First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial
Journal for ImmunoTherapy of Cancer 2023;11:e007279. doi: 10.1136/jitc-2023-007279
Online issue publication 
December 06, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.